Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 5
2005 5
2006 8
2007 12
2008 10
2009 6
2010 2
2011 2
2012 4
2013 8
2014 2
2015 7
2016 22
2017 7
2018 14
2019 23
2020 13
2021 24
2022 17
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Results by year

Filters applied: . Clear all
Page 1
S1‐Guideline Sebaceous Carcinoma.
Utikal J, Nagel P, Müller V, Becker JC, Dippel E, Frisman A, Gschnell M, Griewank K, Hadaschik E, Helbig D, Hillen U, Leiter U, Pföhler C, Krönig L, Ziemer M, Ugurel S. Utikal J, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2024 Apr 28. doi: 10.1111/ddg.15405. Online ahead of print. J Dtsch Dermatol Ges. 2024. PMID: 38679790 Spanish.
Analytical Validation of an Immunohistochemical 7-Biomarker Prognostic Assay (immunoprint®) for Early-Stage Cutaneous Melanoma in Archival Tissue of Patients with AJCC v8 T2-T3 Disease.
Ziemer M, Weidenthaler-Barth B, Gussek P, Pfeiffer M, Kleemann J, Bankov K, Wild PJ, Seibold S, Sureshkumar P, Nickel P, Strobel A, Werner M, Grabbe S. Ziemer M, et al. Diagnostics (Basel). 2023 Sep 29;13(19):3096. doi: 10.3390/diagnostics13193096. Diagnostics (Basel). 2023. PMID: 37835839 Free PMC article.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG. Becker JC, et al. Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Lancet. 2023. PMID: 37451295 Clinical Trial.
S1-Leitlinie dermales und subkutanes Leiomyosarkom.
Helbig D, Dippel E, Erdmann M, Frisman A, Kage P, Leiter U, Mentzel T, Seidel C, Weishaupt C, Ziemer M, Ugurel S. Helbig D, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2023 May;21(5):555-564. doi: 10.1111/ddg.14989_g. J Dtsch Dermatol Ges. 2023. PMID: 37183752
S1-guideline cutaneous and subcutaneous leiomyosarcoma.
Helbig D, Dippel E, Erdmann M, Frisman A, Kage P, Leiter U, Mentzel T, Seidel C, Weishaupt C, Ziemer M, Ugurel S. Helbig D, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2023 May;21(5):555-563. doi: 10.1111/ddg.14989. Epub 2023 Mar 31. J Dtsch Dermatol Ges. 2023. PMID: 36999582
S1-Leitlinie: Mikroskopisch kontrollierte Chirurgie.
Kofler L, Ziemer M, Andrulis M, Horn D, Kulas P, Kunte C, Müller CSL. Kofler L, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2022 Dec;20(12):1663-1675. doi: 10.1111/ddg.14910_g. J Dtsch Dermatol Ges. 2022. PMID: 36508373
S1-Guideline: Microscopically controlled surgery.
Kofler L, Ziemer M, Andrulis M, Horn D, Kulas P, Kunte C, Müller CSL. Kofler L, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2022 Dec;20(12):1663-1674. doi: 10.1111/ddg.14910. Epub 2022 Nov 30. J Dtsch Dermatol Ges. 2022. PMID: 36448272
184 results